Fig. 1: Expression and phosphorylation levels of CDK4/6 downstream substrates and regulators correlate with response to first-line treatment with ET plus CDK4/6 inhibition in MBC patients. | npj Precision Oncology

Fig. 1: Expression and phosphorylation levels of CDK4/6 downstream substrates and regulators correlate with response to first-line treatment with ET plus CDK4/6 inhibition in MBC patients.

From: AKT/mTOR signaling modulates resistance to endocrine therapy and CDK4/6 inhibition in metastatic breast cancers

Fig. 1: Expression and phosphorylation levels of CDK4/6 downstream substrates and regulators correlate with response to first-line treatment with ET plus CDK4/6 inhibition in MBC patients.The alternative text for this image may have been generated using AI.

Diagram showing functional interactions between CDK4/6 and its downstream substrates (a). Box plots with median (center line) and maximum and minimum values (whiskers) show RPPA-based expression and activation levels of CDKs, cyclins, and their downstream substrates. RPPA-based expression and/or phosphorylation of key functional residues of three qualifying biomarkers was significantly higher in patients with progressive disease (PD) compared to responders (R) (b). A statistically significant increase in the expression and activation of signaling molecules involved in Rb regulation was also detected in patients with progressive disease compared to responders (c); p values for two-sided chi-square tests for dichotomized levels of measured biomarkers (above/below the population median) are shown. Samples are color-coded based on patient outcomes.

Back to article page